At the United European Gastroenterology Week 2019, held in Barcelona, Spain, earlier this year, a research team from the Netherlands reported on the prevalence of patients with inflammatory bowel disease (IBD) switching back to the reference infliximab after a previous switch to biosimilar CT-P13, and found that switching back appeared to be effective in patients with IBD.
Among the reasons documented for some patients discontinuing biosimilar infliximab after switching from the reference product are subjective loss of response and adverse events.
At the United European Gastroenterology Week 2019, held in Barcelona, Spain, earlier this year, a research team from the Netherlands reported on the prevalence of patients with inflammatory bowel disease (IBD) switching back to the reference infliximab after a previous switch to biosimilar CT-P13, and found that switching back appeared to be effective in patients with IBD.
In the retrospective, observation, multicenter cohort study, data from patients with IBD who had switched to CT-P13 and had at least 52 weeks of follow-up were eligible for inclusion. In total, 254 patients were switched, 165 of whom had Crohn disease (CD), 52 of whom had ulcerative colitis (UC), and 2 of whom had unclassified IBD.
In total, 35 patients switched back to the originator drug during the follow-up period. Those who made the switch back were more often female than those who remained on the biosimilar. In total, 91.4% of those who switched back did so because of newly reported side effects. Only 3 (8.6%) switched back due to loss of response.
The side effects most commonly reported were skin reactions (37.1%), increased IBD-related symptoms (37.1%), and fatigue (25.7%). Three patients had calprotectin-objectified loss of response.
In 75% of the patients who reported new side effects and in 100% of the patients with loss of response, switching back to the reference product had the desired effect of improving the side effects or regaining response.
The authors concluded that, for those who experience side effects or a loss of response after a switch to the biosimilar product, a switch back may be justified, and appears to have been effective in this group of patients with IBD.
Reference
Mahmmod S, Schultheiss JPD, Mahmmod N, Tan AC, Dijkstra G, Fidder HH. Reverse switching to originator infliximab may be considered in patients with inflammatory bowel diseases experiencing new side effects or loss of response after switching to a CT-P13 biosimilar. Presented at: United European Gastroenterology Week 2019; October 29-23, 2019; Barcelona, Spain.
Patient Perceptions of Switching From the Reference Adalimumab to Amjevita During Its Initial Launch
April 20th 2024In a survey of patients with autoimmune arthritis who had been switched from reference adalimumab (Humira) to biosimilar adalimumab-atto (Amjevita; Amgen), most reported preferring the biosimilar and had no concerns about switching.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Biosimilars Gastroenterology Roundup for January 2024—Podcast Edition
February 4th 2024On this episode of Not So Different, we reminisce on all the major gastroenterology news from January, which brought several reports quantifying how the gastroenterology biosimilar market is progressing and marked the 1-year anniversary of adalimumab biosimilar competition in the US.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
April 10th 2024A report from the Biosimilars Council evaluating IQVIA data found that rebate schemes orchestrated by pharmacy benefit managers (PBMs) are costing US patients and payers billions of dollars by suppressing biosimilar adoption.